ALK and non-small cell lung carcinoma: In one of the clinical trials of NSCLC, the IMpower150 trial, the addition of atezolizumab to bevacizumab plus chemotherapy significantly improved PFS and OS among patients with metastatic NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status [253].